Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Imbalances in Cardiac Output

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinician and patient perspectives on digital technology platforms for healthcare delivery.

Frontiers in digital health·2026

Same author

Initial 4-Year Experience with Microaxial Flow Pumps within a Tertiary Centre in Regional Australia.

Heart, lung & circulation·2026

Same author

The changing landscape of temporary mechanical circulatory support devices in the new heart allocation system: A US nationwide analysis.

JTCVS open·2026

Same author

Building bridges: Extracorporeal membrane oxygenation versus mechanical ventilation as bridge to lung transplant-A nationwide analysis.

JTCVS open·2026

Same author

Sex Differences in Heart Transplantation Outcomes: A 5-Year Review of the 2018 U.S. Allocation Policy.

JACC. Advances·2026

Same author

Impact of renal function on survival in idiopathic pulmonary fibrosis patients 65 years and older undergoing lung transplantation in the United States.

JTCVS open·2026

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Physiologic and pathologic changes in patients with continuous-flow ventricular assist devices.

Ranjit John¹, Andrew Boyle, Frank Pagani

¹Department of Surgery, University of Minnesota, Minneapolis, MN, USA. johnx008@umn.edu

Journal of Cardiovascular Translational Research

|June 19, 2010

Summary

This summary is machine-generated.

Newer continuous-flow pumps for mechanical circulatory support offer better outcomes but present unique management challenges. Understanding these continuous-flow ventricular assist devices (LVADs) is crucial for patient care.

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

Related Experiment Videos

Last Updated: Jun 12, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure

Published on: January 16, 2026

Area of Science:

Cardiology
Biomedical Engineering
Medical Devices

Background:

First-generation pulsatile ventricular assist devices (VADs) have been replaced by continuous-flow (CF) pumps.
CF pumps demonstrate improved durability and reduced complication rates compared to pulsatile VADs.
However, CF pumps introduce novel management issues and risks.

Purpose of the Study:

To overview the physiologic and pathologic effects of continuous-flow pumps.
To discuss the unique management issues and complications associated with CF VADs.
To compare the risks and benefits of CF VADs versus pulsatile VADs.

Main Methods:

Literature review of clinical outcomes and management strategies for CF VADs.
Analysis of physiologic effects of continuous flow on systemic circulation and end-organ function.
Evaluation of unique complications such as thromboembolism, pump thrombosis, gastrointestinal bleeding, and arrhythmias.

Main Results:

CF VADs show superior outcomes and durability over pulsatile VADs.
New challenges include effects on systemic circulation, end-organ function, and device-specific thrombosis.
Increased incidence of gastrointestinal bleeding and ventricular arrhythmias are noted with CF VADs.

Conclusions:

Continuous-flow VADs represent an advancement in mechanical circulatory support.
Effective management requires understanding and addressing the unique risks and complications.
Further research is needed to optimize patient care and long-term outcomes with CF VADs.